Caribou Biosciences
在场
高管
查看带有其 26 名主要高管的组织结构图
Caribou Biosciences 搜索最多的简介
- Rachel Haurwitz, Director, President and Chief Executive Officer
- Ran Zheng, Director
- Nancy Whiting, Director
高管在Caribou Biosciences变化
- Tim Kelly已作为Chief Technology Officer加入公司 (新闻发布的2024一月8号).
- Reigin Zawadzki已作为Chief People Officer加入公司 (新闻发布的2023九月27号).
创建提醒
跟踪 Caribou Biosciences 的高管变动
生物技术
Caribou Biosciences 拥有 2,284 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
- WindRose Health Investors has announced the acquisition of SubjectWell (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
Caribou Biosciences 的最新新闻稿
- Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress | Caribou Biosciences, Inc.
- Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022 | Caribou Biosciences, Inc.
- Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells | Caribou Biosciences, Inc.
- Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy | Caribou Biosciences, Inc.
- Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors | Caribou Biosciences, Inc.
- Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates | Caribou Biosciences, Inc.
- Caribou Biosciences to Present at Upcoming Investor Conference | Caribou Biosciences, Inc.
- Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) | Caribou Biosciences, Inc.
- Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress | Caribou Biosciences, Inc.
- Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting | Caribou Biosciences, Inc.
- View more press releases Close
通过电子邮件
